NCIS success rate for the Haematopoietic Stem Cell Transplant / Bone Marrow Transplant Programme is comparable to the international registry data at the Centre for International Blood & Marrow Transplant Research (CIBMTR) and the European Group for Blood and Marrow Transplant (EBMT).
|Type of transplant||Diagnosis||NCIS Success Rate||International Registry Success Rate||Reference|
|Matched Sibling Donor (MSD) Transplant||Acute Leukaemia||~50% at 5 years (2005 - 2016)||~50% at 5 years (2001 - 2018), CIBMTR||Cheryl Lim, Koh LP et al. EBMT 2017|
|Matched Unrelated (Volunteer) Donor (MUD) Transplant||Acute Leukaemia||~50% at 5 years (2005 - 2016)||~50% at 5 years (2001 - 2018), CIBMTR||Cheryl Lim, Koh LP et al. EBMT 2017|
|Unrelated Umbilical Cord Blood (UCB) Transplant||Haematological Cancers (Leukemia, Lymphoma, Myelodysplastic Syndromes)||~50% at 3 years (2007 - 2019)||~40% at 5 years (2005 - 2016), EBMT||Ian Wu, Koh LP et al. ASH 2020. Ruggeri A, et al. Leukemia 2015.|
|Sequential Transplant Using Matched Related/Unrelated Donor||Haematological Cancers||~60% at 3 years (2006 - 2020)||~55% at 3 years (2007 - 2019) (EBMT)||Chong LL, Koh LP, et al. ASH 2020. Malard F, et al. BBMT 2017|
- Centre for International Blood & Marrow Transplant Research, www.cibmtr.org
- European Group for Blood and Marrow Transplantation, www.ebmt.org
(Information is correct as at July 2022)
The following table shows the survival information of patients diagnosed with non–small cell lung cancer (NSCLC) at NCIS between 2015 to 2019. The 5-year survival rate reflects the precentage of these patients who remain alive at the 5th year, according to their diagnosed NSCLC stage.